Aberrant methylation ofE-cadherinandH-cadheringenes in nonsmall cell lung cancer and its relation to clinicopathologic features

Cancer ◽  
2007 ◽  
Vol 110 (12) ◽  
pp. 2785-2792 ◽  
Author(s):  
Dong Sun Kim ◽  
Mi Jin Kim ◽  
Ji Yun Lee ◽  
Young Zoo Kim ◽  
Eun Jin Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Aberrant Methylation ◽  
Clinicopathologic Features

scholarly journals Assessment of Chemosensitivity-related Aberrant Methylation of Nonsmall Cell Lung Cancer by EBUS-TBNA

2009 ◽  
Vol 16 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Takahiro Nakajima ◽  
Kazuhiro Yasufuku ◽  
Makoto Suzuki ◽  
Taiki Fujiwara ◽  
Kiyoshi Shibuya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Aberrant Methylation

scholarly journals Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer

Cancer ◽  
2008 ◽  
Vol 113 (6) ◽  
pp. 1396-1403 ◽  
Author(s):  
Lei Tian ◽  
Makoto Suzuki ◽  
Takahiro Nakajima ◽  
Rieko Kubo ◽  
Yasuo Sekine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Prostaglandin E ◽  
Aberrant Methylation

scholarly journals Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

2021 ◽  
Vol 9 (3) ◽  
pp. e002262
Author(s):  
Justin Ferdinandus ◽  
Martin Metzenmacher ◽  
Lukas Kessler ◽  
Lale Umutlu ◽  
Clemens Aigner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Standard Of Care ◽  
Nonsmall Cell Lung Cancer ◽  
Published Data ◽  
Complete Metabolic Response ◽  
Positron Emission ◽  
Checkpoint Inhibitor Therapy

IntroductionImmunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.MethodsThis is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. ResultsOut of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months.ConclusionAfter a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.

scholarly journals Aberrantp16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer

2003 ◽  
Vol 106 (6) ◽  
pp. 913-918 ◽  
Author(s):  
Sonata Jarmalaite ◽  
Annamaria Kannio ◽  
Sisko Anttila ◽  
Juozas R. Lazutka ◽  
Kirsti Husgafvel-Pursiainen
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Nonsmall Cell Lung Cancer ◽  
Former Smokers

scholarly journals Aberrant methylation modifications reflect specific drug responses in small cell lung cancer

Genomics ◽  
2021 ◽  
Vol 113 (3) ◽  
pp. 1114-1126
Author(s):  
Peixin Chen ◽  
Haoyue Guo ◽  
Yu Liu ◽  
Bin Chen ◽  
Sha Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Specific Drug ◽  
Small Cell Lung ◽  
Drug Responses
Sign in / Sign up

Export Citation Format

Share Document